文献速递慢阻肺呼吸危重症与机械通气

美国肺部疾病患者临终住院费用分析

Costs of End-of-Life Hospitalizations in the United States for People With Pulmonary Diseases.
PubMed 文献 · Chest · 2024-01-13

该研究基于2009至2019年美国全国住院患者样本数据,纳入18至74岁因肺部疾病住院的成人,排除有肺移植史者,分析临终住院费用及趋势。结果显示,肺部疾病住院中4.1%发生院内死亡,阻塞性肺病占住院的94.1%和院内死亡的88.1%;临终住院平均费用为29,981美元,诊断和操作使用差异大;机械通气、ECMO和透析使用随时间显著增加,医院转院率上升。

要点

  • 肺部疾病住院中4.1%发生院内死亡,阻塞性肺病占住院94.1%和院内死亡88.1%。
  • 临终住院平均费用为29,981美元,年轻且接受更多操作者费用更高。
  • 机械通气、ECMO和透析使用及医院转院率在研究期间显著增加。

核心结论

  • 临终住院费用因人而异,但构成显著医疗支出,对部分接受肺移植者可避免。
  • 这些费用应纳入肺移植成本效果研究。

研究设计与样本

  • 研究基于2009至2019年成本与利用项目全国住院患者样本数据。
  • 纳入18至74岁因肺部疾病住院的成人,排除有肺移植史者。
  • 使用ICD编码识别肺部疾病入院、并发症、操作和干预。
  • 计算住院总费用并按出院时患者状态分层。
  • 按人口学和医院因素评估费用随时间趋势。

主要发现

  • 阻塞性肺病占住院的94.1%和院内死亡的88.1%。
  • 临终住院平均费用为29,981美元,随诊断和操作使用差异大。
  • 年轻且接受更多操作者住院费用最高。
  • 机械通气、ECMO和透析使用在研究期间显著增加,医院转院率上升且院内死亡入院中增幅更大。

临床怎么用

  • 临床医生应关注肺部疾病临终住院的费用差异,尤其年轻和接受更多操作者。
  • 机械通气、ECMO和透析使用增加及转院率上升提示需评估临终关怀资源配置。
  • 肺移植成本效果分析中应考虑临终住院费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung transplantation is a lifesaving intervention for people with advanced lung disease, but it is costly and resource-intensive. To investigate the cost-effectiveness of lung transplantation as a treatment option in pulmonary disease, we must understand costs attributable to end-of-life hospitalizations for end-stage lung disease. RESEARCH QUESTION: What are the costs associated with end-of-life hospitalizations for people with pulmonary disease, and how have these trends changed over time? STUDY DESIGN AND METHODS: Adults aged 18 to 74 years with hospitalization data in the Cost and Utilization Project National Inpatient Sample data from 2009 to 2019 with a pulmonary disease admission were included in this analysis. Those with a history of lung transplantation were excluded. International Classification of Diseases codes were used to identify pulmonary disease admissions, complications, and procedures and interventions. Total charges were calculated for hospitalizations and stratified by patient status at time of discharge. Trends in charges over time were assessed by demographic and hospital factors. RESULTS: One hundred nine thousand nine hundred twenty-four (4.1%) hospital admissions for pulmonary disease resulted in in-hospital mortality. Those with obstructive lung disease accounted for 94.1% of hospitalizations and 88.1% cases of in-hospital mortality. Estimated costs for end-of-life hospitalizations were $29,981 on average with wide variation in cost by diagnosis and procedure utilization. Inpatient costs were highest for younger people who received more procedures. Among the most expensive admissions, mechanical ventilation accounted for the greatest proportion of interventions. Significant increases in the use of mechanical ventilation, extracorporeal membrane oxygenation, and dialysis occurred over the time period. The rate of hospital transfers increased with a proportionately greater increase across admissions resulting in in-hospital mortality. INTERPRETATION: Costs accrued during end-of-life hospitalizations vary across people but represent a significant health care cost that can be averted for selected people who undergo lung transplantation. These costs should be considered in studies of cost-effectiveness in lung transplantation.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Lehr CJ, Dewey E, Udeh B, et al. Costs of End-of-Life Hospitalizations in the United States for People With Pulmonary Diseases. Chest. 2024. PMID: 38224779. doi:10.1016/j.chest.2024.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。